Merck Ownership
| MRK Stock | USD 100.06 1.13 1.12% |
Shares in Circulation | First Issued 1985-09-30 | Previous Quarter 2.5 B | Current Value 2.5 B | Avarage Shares Outstanding 2.5 B | Quarterly Volatility 271.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Merck |
Merck Stock Ownership Analysis
About 79.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.07. Merck Company last dividend was issued on the 16th of December 2024. The entity had 1048:1000 split on the 3rd of June 2021. Merck Co., Inc. operates as a healthcare company worldwide. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 67000 people. To find out more about Merck Company contact Kenneth Frazier at 908 740 4000 or learn more at https://www.merck.com.Besides selling stocks to institutional investors, Merck also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Merck's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Merck's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Merck Quarterly Liabilities And Stockholders Equity |
|
Merck Insider Trades History
Less than 1% of Merck Company are currently held by insiders. Unlike Merck's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Merck's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Merck's insider trades
Merck Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Merck is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Merck Company backward and forwards among themselves. Merck's institutional investor refers to the entity that pools money to purchase Merck's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Legal & General Group Plc | 2024-09-30 | 23.6 M | T. Rowe Price Associates, Inc. | 2024-09-30 | 22.5 M | Deutsche Bank Ag | 2024-09-30 | 19.6 M | Charles Schwab Investment Management Inc | 2024-09-30 | 18.8 M | Bank Of New York Mellon Corp | 2024-09-30 | 18.7 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 17.8 M | Ameriprise Financial Inc | 2024-09-30 | 17.2 M | Royal Bank Of Canada | 2024-09-30 | 16.6 M | Amundi | 2024-09-30 | 16.1 M | Vanguard Group Inc | 2024-09-30 | 249.8 M | Blackrock Inc | 2024-06-30 | 207.3 M |
Merck Company Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Merck insiders, such as employees or executives, is commonly permitted as long as it does not rely on Merck's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Merck insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Smart Dalton over six months ago Disposition of 612 shares by Smart Dalton of Merck subject to Rule 16b-3 | ||
Smart Dalton over six months ago Disposition of 381 shares by Smart Dalton of Merck subject to Rule 16b-3 | ||
Smart Dalton over six months ago Disposition of 6224 shares by Smart Dalton of Merck at 117.89 subject to Rule 16b-3 | ||
Smart Dalton over six months ago Disposition of 6224 shares by Smart Dalton of Merck at 117.89 subject to Rule 16b-3 | ||
Peter Wendell over a year ago Merck exotic insider transaction detected | ||
Peter Wendell over a year ago Acquisition by Peter Wendell of 270 shares of Merck subject to Rule 16b-3 |
Merck's latest congressional trading
Congressional trading in companies like Merck Company, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Merck by those in governmental positions are based on the same information available to the general public.
| 2024-12-09 | Representative Jared Moskowitz | Acquired Under $15K | Verify | ||
| 2024-11-14 | Representative Michael McCaul | Acquired $50K to $100K | Verify | ||
| 2024-11-11 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
| 2024-10-14 | Representative Jonathan Jackson | Acquired $15K to $50K | Verify | ||
| 2024-10-11 | Representative Jonathan Jackson | Acquired $15K to $50K | Verify | ||
| 2024-10-08 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
| 2024-09-06 | Representative John James | Acquired Under $15K | Verify | ||
| 2024-08-21 | Representative Jared Moskowitz | Acquired Under $15K | Verify | ||
| 2024-08-20 | Representative C Scott Franklin | Acquired Under $15K | Verify | ||
| 2024-08-16 | Representative Kathy Manning | Acquired Under $15K | Verify | ||
| 2024-05-02 | Representative Michael C Burgess | Acquired Under $15K | Verify | ||
| 2024-01-22 | Representative Jared Moskowitz | Acquired Under $15K | Verify | ||
| 2023-11-16 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-11-15 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-10-20 | Senator Pete Ricketts | Acquired $50K to $100K | Verify | ||
| 2023-10-03 | Representative Michael C Burgess | Acquired Under $15K | Verify | ||
| 2023-05-26 | Representative Rick Larsen | Acquired Under $15K | Verify | ||
| 2023-03-10 | Representative Jared Moskowitz | Acquired Under $15K | Verify | ||
| 2022-12-22 | Representative Michael McCaul | Acquired $100K to $250K | Verify | ||
| 2022-06-16 | Representative Lois Frankel | Acquired Under $15K | Verify | ||
| 2022-04-08 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2022-04-07 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2022-03-09 | Representative Robert J Wittman | Acquired Under $15K | Verify | ||
| 2021-11-28 | Representative Bob Gibbs | Acquired Under $15K | Verify | ||
| 2021-10-29 | Representative Gus M Bilirakis | Acquired Under $15K | Verify | ||
| 2021-08-06 | Representative John Curtis | Acquired Under $15K | Verify | ||
| 2021-07-08 | Senator John W Hickenlooper | Acquired Under $15K | Verify | ||
| 2021-04-06 | Representative Richard W Allen | Acquired $15K to $50K | Verify | ||
| 2021-01-07 | Representative Michael T McCaul | Acquired $50K to $100K | Verify | ||
| 2020-08-18 | Representative Richard W Allen | Acquired $15K to $50K | Verify | ||
| 2020-04-27 | Representative Lois Frankel | Acquired Under $15K | Verify | ||
| 2020-04-13 | Representative Robert J Wittman | Acquired Under $15K | Verify | ||
| 2020-03-23 | Representative Lois Frankel | Acquired Under $15K | Verify | ||
| 2019-05-07 | Senator David Perdue | Acquired $15K to $50K | Verify | ||
| 2019-01-17 | Senator James Inhofe | Acquired $100K to $250K | Verify | ||
| 2018-07-10 | Senator Susan M Collins | Acquired Under $15K | Verify | ||
| 2018-07-09 | Senator Susan M Collins | Acquired Under $15K | Verify | ||
| 2017-12-05 | Senator David Perdue | Acquired $15K to $50K | Verify | ||
| 2017-10-02 | Senator David Perdue | Acquired Under $15K | Verify | ||
| 2016-02-08 | Senator John Hoeven | Acquired $50K to $100K | Verify | ||
| 2015-09-10 | Senator James Inhofe | Acquired $15K to $50K | Verify |
Merck Outstanding Bonds
Merck issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Merck Company uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Merck bonds can be classified according to their maturity, which is the date when Merck Company has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MRK 29 10 DEC 61 Corp BondUS58933YBG98 | View | |
| MERCK INC Corp BondUS58933YAZ88 | View | |
| MERCK INC Corp BondUS58933YAY14 | View | |
| MERCK INC Corp BondUS58933YAX31 | View | |
| MERCK INC Corp BondUS58933YAW57 | View | |
| MERCK INC Corp BondUS58933YAV74 | View | |
| MRK 275 10 DEC 51 Corp BondUS58933YBF16 | View | |
| MRK 215 10 DEC 31 Corp BondUS58933YBE41 | View |
Merck Corporate Filings
8K | 22nd of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 6th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 4th of November 2024 Other Reports | ViewVerify | |
F4 | 1st of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Dividend Share 3.04 | Earnings Share 4.78 | Revenue Per Share 24.931 | Quarterly Revenue Growth 0.044 |
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.